Literature DB >> 9636373

Differential association of uracil DNA glycosylase with SIVSM Vpr and Vpx proteins.

R Sleigh1, M Sharkey, M A Newman, B Hahn, M Stevenson.   

Abstract

The HIV-1 Vpr protein is a virion-associated protein which has been shown to facilitate infection of nondividing macrophages and additionally to alter cell cycle and proliferation status of the infected host cell. HIV-1 Vpr also was recently shown to associate with the DNA repair enzyme uracil DNA glycosylase (UDG). This association with a DNA repair enzyme is intriguing given that nonprimate lentiviruses encode a dUTPase, which, like UDG, minimizes the misincorporation of uracil into DNA and is important for virus replication in primary nondividing macrophages but not in dividing cells. This raises the possibility that the dependence upon Vpr for infection of nondividing macrophages may relate to its ability to interact with UDG. Members of the HIV-2/SIVSM group encode, in addition to Vpr, a related protein called Vpx. We previously demonstrated (Fletcher et al., 1996) that Vpx of HIV-2/SIVSM is necessary and sufficient for infection of primary macaque macrophages, while Vpr is not required for macrophage infection but governs cell cycle arrest. Here, we extend on these observations by demonstrating that Vpr, but not Vpx of HIV-2/SIVSM, associates with UDG, which suggests that Vpx facilitates infection of macrophages by a UDG-independent mechanism.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9636373      PMCID: PMC9524214          DOI: 10.1006/viro.1998.9159

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.513


  42 in total

1.  Distinct subsets of retroviruses encode dUTPase.

Authors:  J H Elder; D L Lerner; C S Hasselkus-Light; D J Fontenot; E Hunter; P A Luciw; R C Montelaro; T R Phillips
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

2.  The specific binding of nuclear protein(s) to the cAMP responsive element (CRE) sequence (TGACGTCA) is reduced by the misincorporation of U and increased by the deamination of C.

Authors:  A Verri; P Mazzarello; G Biamonti; S Spadari; F Focher
Journal:  Nucleic Acids Res       Date:  1990-10-11       Impact factor: 16.971

Review 3.  Biology and pathogenesis of lentiviruses.

Authors:  O Narayan; J E Clements
Journal:  J Gen Virol       Date:  1989-07       Impact factor: 3.891

4.  Use of the two-hybrid system to identify the domain of p53 involved in oligomerization.

Authors:  K Iwabuchi; B Li; P Bartel; S Fields
Journal:  Oncogene       Date:  1993-06       Impact factor: 9.867

5.  Pyrimidine nucleotide and nucleic acid synthesis in human monocytes and macrophages.

Authors:  C Terai; D A Carson
Journal:  Exp Cell Res       Date:  1991-04       Impact factor: 3.905

6.  Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM).

Authors:  T M Fletcher; B Brichacek; N Sharova; M A Newman; G Stivahtis; P M Sharp; M Emerman; B H Hahn; M Stevenson
Journal:  EMBO J       Date:  1996-11-15       Impact factor: 11.598

7.  Nuclear and mitochondrial forms of human uracil-DNA glycosylase are encoded by the same gene.

Authors:  G Slupphaug; F H Markussen; L C Olsen; R Aasland; N Aarsaether; O Bakke; H E Krokan; D E Helland
Journal:  Nucleic Acids Res       Date:  1993-06-11       Impact factor: 16.971

8.  Molecular cloning and characterization of deoxyuridine triphosphatase from feline immunodeficiency virus (FIV).

Authors:  P C Wagaman; C S Hasselkus-Light; M Henson; D L Lerner; T R Phillips; J H Elder
Journal:  Virology       Date:  1993-10       Impact factor: 3.616

9.  Induction of cell differentiation by human immunodeficiency virus 1 vpr.

Authors:  D N Levy; L S Fernandes; W V Williams; D B Weiner
Journal:  Cell       Date:  1993-02-26       Impact factor: 41.582

10.  Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus.

Authors:  P F Lewis; M Emerman
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

View more
  7 in total

1.  Interaction of Vpx and apolipoprotein B mRNA-editing catalytic polypeptide 3 family member A (APOBEC3A) correlates with efficient lentivirus infection of monocytes.

Authors:  André Berger; Carsten Münk; Matthias Schweizer; Klaus Cichutek; Silke Schüle; Egbert Flory
Journal:  J Biol Chem       Date:  2010-02-23       Impact factor: 5.157

2.  Cullin4A and cullin4B are interchangeable for HIV Vpr and Vpx action through the CRL4 ubiquitin ligase complex.

Authors:  Hamayun John Sharifi; Andrea K M Furuya; Robert M Jellinger; Michael D Nekorchuk; Carlos M C de Noronha
Journal:  J Virol       Date:  2014-04-09       Impact factor: 5.103

3.  The interaction of vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 In vivo mutation rate.

Authors:  L M Mansky; S Preveral; L Selig; R Benarous; S Benichou
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

4.  Restriction of HIV-1 replication in monocytes is abolished by Vpx of SIVsmmPBj.

Authors:  Silke Schüle; Björn-Philipp Kloke; Julia K Kaiser; Sabine Heidmeier; Sylvia Panitz; Nina Wolfrum; Klaus Cichutek; Matthias Schweizer
Journal:  PLoS One       Date:  2009-09-21       Impact factor: 3.240

5.  HIV-1 and HIV-2 exhibit divergent interactions with HLTF and UNG2 DNA repair proteins.

Authors:  Kasia Hrecka; Caili Hao; Ming-Chieh Shun; Sarabpreet Kaur; Selene K Swanson; Laurence Florens; Michael P Washburn; Jacek Skowronski
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-22       Impact factor: 11.205

6.  Vpx is required for dissemination and pathogenesis of SIV(SM) PBj: evidence of macrophage-dependent viral amplification.

Authors:  V M Hirsch; M E Sharkey; C R Brown; B Brichacek; S Goldstein; J Wakefield; R Byrum; W R Elkins; B H Hahn; J D Lifson; M Stevenson
Journal:  Nat Med       Date:  1998-12       Impact factor: 87.241

7.  Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction.

Authors:  Natalia Sharova; Yuanfei Wu; Xiaonan Zhu; Ruzena Stranska; Rajnish Kaushik; Mark Sharkey; Mario Stevenson
Journal:  PLoS Pathog       Date:  2008-05-02       Impact factor: 6.823

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.